Bernstein reiterates Mondelez stock rating on solid Q1 results By Investing.com

Mondelez reported Q1 2026 EPS of $0.67 versus $0.61 consensus and revenue of $10.08 billion, beating forecasts by 3.38%, with organic growth of 3.0% versus 0.6% expected. Bernstein reiterated an Outperform rating with a $74 target, while TD Cowen raised its target to $67 from $65. Guidance for FY2026 was left unchanged due to Middle East conflict-related headwinds, though analysts still see the stock as attractive below $60.

Analysis

The key signal is not the quarter itself, but the re-rating path from “defensive staple with near-term commodity noise” to “self-help earnings compounder.” If cocoa has already rolled over in Europe and management can hold pricing while volume elasticity stays contained, the next leg is margin normalization rather than top-line acceleration — that is typically what expands multiples in packaged food. The market is still pricing MDLZ as if geopolitics and input volatility permanently cap EPS power, which creates a disconnect if 2026 stays merely stable and 2027 inflects back to algorithmic growth.

The second-order winner is the supply chain, not just MDLZ: lower cocoa pressure should ease working-capital strain and improve order visibility for ingredient suppliers and logistics partners tied to snack volumes. The loser is any competitor relying on sharper price cuts or more aggressive promotions to gain share; if MDLZ can defend shelf space without sacrificing elasticity, rivals may be forced into margin-negative behavior to keep up. That dynamic matters over the next 2-3 quarters more than the current quarter beat.

The main risk is that unchanged guidance becomes a ceiling if Middle East-related disruption spreads beyond the stated sales exposure and forces either trade friction or incremental freight/insurance costs. In that scenario, the stock’s current move could fade over days to weeks because investors will treat the beat as one-off while waiting for cleaner guidance. Longer term, however, the setup is attractive if earnings revisions continue to rise; this is a classic case where a low-teens multiple can expand on even low-single-digit EPS growth once visibility improves.

The contrarian miss is that consensus may be underestimating how fast valuation can re-rate when a defensive name stops being a “commodity casualty” and becomes a “clean comp and pricing” story. At under $60, the market is effectively paying for no normalization in 2027, which looks too conservative if algorithmic growth resumes. The setup is asymmetric: limited downside if guidance stays steady, but meaningful upside if the next two prints confirm that margin pressure is peaking.

Key Decisions for Investors

• Go long MDLZ on a 3-6 month horizon; add on pullbacks below $60. Risk/reward is attractive if the stock re-rates toward the low/mid-$60s on continued estimate revisions, with downside buffered by staple-like demand.
• Use a call spread in MDLZ (e.g., 6-9 month 60/70 calls) to express upside from multiple expansion while capping premium outlay; best if you expect gradual rather than immediate re-rating.
• Pair trade: long MDLZ / short a higher-beta packaged food or snack peer with more exposure to input-cost volatility. Thesis: MDLZ gets cleaner earnings visibility first, while the short leg is more vulnerable if cocoa relief becomes a sector-wide margin squeeze.
• Monitor for a second-quarter follow-through on analyst revisions; if upward estimate revisions continue into the next print, add to the long. If guidance tightens despite stable demand, reduce exposure quickly because the stock’s thesis depends on normalization continuing.
• For event risk, hedge with short-dated puts only around geopolitical flare-ups; the stock should not need permanent downside protection unless Middle East disruption widens materially beyond current exposure.